Abstract
Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have